OLD National Bancorp IN Grows Position in Edwards Lifesciences Co. (NYSE:EW)

OLD National Bancorp IN grew its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 197,143 shares of the medical research company's stock after acquiring an additional 7,066 shares during the period. OLD National Bancorp IN's holdings in Edwards Lifesciences were worth $14,594,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Plimoth Trust Co. LLC bought a new position in Edwards Lifesciences in the fourth quarter worth about $205,000. Strategic Blueprint LLC bought a new position in Edwards Lifesciences in the fourth quarter worth about $203,000. Mount Yale Investment Advisors LLC raised its stake in Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock worth $634,000 after buying an additional 162 shares in the last quarter. United Asset Strategies Inc. raised its stake in Edwards Lifesciences by 5.2% in the fourth quarter. United Asset Strategies Inc. now owns 168,159 shares of the medical research company's stock worth $12,449,000 after buying an additional 8,242 shares in the last quarter. Finally, Union Bancaire Privee UBP SA bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $1,120,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company's stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,000 shares of company stock worth $2,195,180. Insiders own 1.29% of the company's stock.

Analyst Ratings Changes

EW has been the subject of a number of analyst reports. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a "hold" rating in a research note on Thursday, December 5th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 28th. The Goldman Sachs Group raised their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, December 5th. Morgan Stanley reaffirmed an "equal weight" rating and set a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, Royal Bank of Canada increased their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $79.19.

Edwards Lifesciences Price Performance

Shares of EW stock traded down $0.81 on Friday, hitting $72.41. 3,237,492 shares of the stock traded hands, compared to its average volume of 4,686,934. The firm has a market cap of $42.71 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 3.65 and a beta of 1.11. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a 50 day simple moving average of $72.45 and a two-hundred day simple moving average of $70.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.